Exelixis (EXEL) Stock Forecast & Price Target

$34.65 +0.24 (+0.70%)

(As of 11/20/2024 ET)

Exelixis - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
1

Hold
5

Buy
14

Based on 20 Wall Street analysts who have issued ratings for Exelixis in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 1 has given a sell rating, 5 have given a hold rating, and 14 have given a buy rating for EXEL.

Consensus Price Target

$31.44
-9.25% Downside

According to the 20 analysts' twelve-month price targets for Exelixis, the average price target is $31.44. The highest price target for EXEL is $38.00, while the lowest price target for EXEL is $25.00. The average price target represents a forecasted downside of -9.25% from the current price of $34.65.

Get the Latest News and Ratings for EXEL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Exelixis and its competitors.

EXEL Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	10 Buy rating(s)	10 Buy rating(s)	11 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$31.44	$29.57	$27.43	$25.44
Forecasted Upside	-9.25% Downside	2.57% Upside	5.98% Upside	18.31% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

EXEL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EXEL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Exelixis Stock vs. The Competition

Type	Exelixis	Medical Companies	S&P 500
Consensus Rating Score	2.65	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	-9.25% Downside	26,904.61% Upside	9.81% Upside
News Sentiment Rating	Positive News See Recent EXEL News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/30/2024	Stephens 4 of 5 stars	S. Loganathan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$23.00 ➝ $29.00	-11.69%
10/30/2024	Guggenheim 3 of 5 stars		Boost Target	Buy ➝ Buy	$32.00 ➝ $33.00	+0.49%
10/30/2024	Piper Sandler 2 of 5 stars		Boost Target	Overweight ➝ Overweight	$33.00 ➝ $36.00	+10.67%
10/30/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$34.00 ➝ $34.00	+4.20%
10/30/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$32.00 ➝ $36.00	+8.47%
10/30/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$33.00 ➝ $38.00	+14.49%
Get the Latest News and Ratings for EXEL and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.
10/30/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$29.00 ➝ $36.00	+13.03%
10/21/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$27.00 ➝ $34.00	+18.55%
10/16/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$26.00 ➝ $30.00	+5.26%
10/15/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Shibutani Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
10/15/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$30.00 ➝ $32.00	+12.72%
10/11/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Outperform ➝ Market Outperform	$29.00 ➝ $29.00	+10.35%
10/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$26.00 ➝ $28.00	+6.63%
9/19/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Verma Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$30.00	+11.86%
9/18/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $29.00	+5.07%
7/30/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$29.00 ➝ $29.00	+25.22%
5/1/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
4/11/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$25.00	+5.57%
12/19/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$27.00	+15.68%
12/15/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$31.00	+32.99%
8/8/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Liu Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
8/8/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$18.00	-11.11%
8/8/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$18.00	-11.11%
3/3/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$24.00	+43.97%
1/26/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$29.00	+67.34%
1/9/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$21.00 ➝ $20.00	+15.81%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:57 AM ET.

EXEL Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Exelixis is $31.44, with a high forecast of $38.00 and a low forecast of $25.00.
: 20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There is currently 1 sell rating, 5 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EXEL shares.
: According to analysts, Exelixis's stock has a predicted downside of -9.25% based on their 12-month stock forecasts.
: Over the previous 90 days, Exelixis's stock had 1 upgrade by analysts.
: Exelixis has been rated by research analysts at Bank of America, BMO Capital Markets, Guggenheim, HC Wainwright, JMP Securities, Morgan Stanley, Piper Sandler, Royal Bank of Canada, Stephens, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Exelixis less than other "medical" companies. The consensus rating score for Exelixis is 2.65 while the average consensus rating score for "medical" companies is 2.80. Learn more on how EXEL compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)

The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…

Claim your FREE 2024 Gold Guide

This page (NASDAQ:EXEL) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exelixis (EXEL) Stock Forecast & Price Target